China SXT Pharmaceuticals shares surge 727.81% after-hours after announcing $10M registered direct offering with single investor.

China SXT Pharmaceuticals Inc. surged 727.81% in after-hours trading following the announcement of a $10 million registered direct offering through the sale of 66.67 million Class A ordinary shares at $0.15 per share. The offering, set to close on January 12, 2026, was executed at a significant discount to its current trading price of $0.36, signaling confidence in the company’s financial strategy despite potential dilution. The proceeds will support operations, and the news coincided with the company’s launch of an AI-driven Strategic Artificial Intelligence Insights Initiative, enhancing market perception of its growth potential. Investors interpreted the capital raise as a strategic move to strengthen liquidity and fund innovation, outweighing concerns about share dilution. The transaction, facilitated by Univest Securities, was conducted under an effective SEC registration statement, reinforcing regulatory compliance and investor trust.